

## NEWSLETTER

### CHEMICAL & PHARMACEUTICAL 23 - 29 March 2026



#### **US-Iran Conflict Spills: Helium, Pharmaceuticals, and Fertilizer Supply Chains in Crisis**

The ongoing US-Iran conflict has directly impacted the oil supply chain, frequently making headlines. The effects of this geopolitical conflict have already transcended energy boundaries, severely disrupting the global flow of various key raw materials and commodities. Helium, pharmaceuticals, and fertilizers have all been significantly affected. **(ChemNet Chemical Headlines)**

#### **India Initiates First Anti-dumping Investigation Against China**

On March 20, 2026, the Indian Ministry of Commerce and Industry announced that, in response to an application submitted by Silox India Private Limited, a domestic Indian company, it has initiated the first anti-dumping sunset review investigation on sodium hydrosulphite originating in or imported from China. This case involves products under Indian Customs Codes 28311010 and 28321020. **(ChemNet Chemical Headlines)**

#### **China's First 10,000-Ton Photovoltaic Hydrogen Production Project Achieves Large-Scale Filling**

Ordos Hanxia New Energy Co., Ltd. successfully completed its first tube-type container hydrogen filling task for 2026. The filling yielded 423 kg of hydrogen with a purity of 99.999%, meeting the national standard for superior quality. This marks a new stage in the coordinated development of large-scale filling and multi-scenario consumption for China's first 10,000-ton photovoltaic hydrogen production project. **(ChemNet Chemical Headlines)**

#### **Shanghai impresses global biotech, pharma markets with quality growth**

Shanghai's biopharma sector is gaining global recognition through robust growth and international partnerships. In 2024, Shanghai firms accounted for \$30.7 billion (26.4 billion euro) in licensing deals, nearly one-third of China's total. The city's supportive ecosystem, talent and collaboration enable companies to expand worldwide. **(China Daily)**

#### **China approves world's 1st domestic drug for hepatitis B cure**

China has approved Pegbing, the world's first drug aimed at achieving a functional cure for hepatitis B. Developed domestically by Amoytop Biotech, the injectable treatment is designed for use with antiviral medication to enable sustained viral clearance. This approval marks a significant advancement against the disease, which affects millions globally. **(China Daily)**